Knowing early can make a difference

A new way to get earlier, more precise information after cancer treatment
What is molecular residual disease (MRD)?

MRD is the presence of small traces of cancer in the blood, such as circulating tumor DNA (ctDNA) or microscopic pieces of tumor DNA.
Why is cancer surveillance important?

Knowing early if there are traces of cancer present in your body can help the doctor or oncologist decide:

• If you are responding to treatment
• If further cancer treatment needs to be considered
• If there are signs that the cancer has returned or progressed

The most common imaging tools used to detect the presence of cancer include computerized tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan and mammography. These imaging tools are limited in their ability to detect molecular residual disease (MRD), or very small traces of cancer in the body. If left untreated, residual cancer cells are highly likely to multiply and cause a recurrence.
Signatera is a new cancer surveillance test uniquely personalized for each patient

Signatera is a custom-designed test that is based on each patient’s unique set of tumor mutations.

Knowing earlier if your cancer is likely to recur or has progressed after treatment can help you have a more informed discussion with your doctor on how to continue to treat or to detect changes in your disease.

How is the Signatera test performed?

1. An analysis of both blood and tissue determines your unique set of tumor mutations

2. The test is custom-built and personalized for you

3. The test can detect the presence or absence of tumor DNA throughout your treatment
How long will it take to receive my test results?

Designing your first Signatera test
The first time the Signatera test is ordered, it will take 2 to 3 weeks to design your personalized test.

After your test has been designed
It will take 1 week for your test results to become available to your physician.

What do my test results mean?

If you have early-stage cancer:

<table>
<thead>
<tr>
<th>ctDNA</th>
<th>Higher risk for your cancer returning</th>
</tr>
</thead>
<tbody>
<tr>
<td>ctDNA</td>
<td>More likely to remain cancer-free</td>
</tr>
</tbody>
</table>

The Signatera test is recommended for periodic use over the course of your treatment as directed by your doctor to detect the presence of disease.
How accurate is Signatera?

Signatera can detect extremely small amounts of tumor DNA before cancer recurrence can be seen by traditional imaging tools such as CT scans or MRI. The Signatera test is highly sensitive; this means that if your test result is positive, there is a high likelihood that your cancer may recur without further treatment.

How much does Signatera cost?

At Natera, we understand that medical tests and billing processes can be confusing. We welcome all insurance plans and will work with you so that cost is not a barrier for testing. We also have an affordable cash pay rate for those patients who do not wish to use insurance.
When should the Signatera test be considered?

- After surgery, to detect the presence of any residual disease
- During treatment, to evaluate treatment response
- After treatment, to monitor for early recurrence

Natera offers Medicare coverage for Stage II-III colorectal cancer (CRC). Talk to your doctor for more information.

For questions or financial assistance, please contact Natera’s Patient Coordinators.

Phone: 650.489.9050
Fax: 650.412.1962
Email: signaterapc@natera.com
For more information about Signatera or to review published studies, visit www.natera.com/signatera

Contact Natera’s Patient Coordinators by calling 650.489.9050

Brought to you by Natera, a global leader in genetic testing and cell-free DNA analysis

About Natera, the maker of Signatera
Natera is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide by harnessing the power of DNA from a single blood sample to improve the management of reproductive health, cancer and organ transplants.

The test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2020 Natera, Inc. All Rights Reserved. SGN_PT_SLIM_BRO_20200918_NAT-8020070